Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer
| Autor: | Azim Jalali, Jeanne Tie, Rachel Wong, Sarah J. Banks, Lucy Gately, Belinda Lee, Margaret Lee, Matthew Loft, Grace Gard, Catherine Dunn, Adnan Khattak, Hui-Li Wong, Ross Jennens, Justin M. C. Yeung, Peter Gibbs, Joseph McKendrick, Suzanne Kosmider, Sumitra Ananda, L. Lim, Jeremy Shapiro |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
medicine.medical_specialty animal structures Pyrrolidines Colorectal cancer medicine.medical_treatment Population Trifluridine chemistry.chemical_compound Refractory Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans education Uracil Tipiracil Retrospective Studies Chemotherapy education.field_of_study business.industry Rectal Neoplasms Australia Cancer Middle Aged medicine.disease Drug Combinations Clinical research Oncology chemistry Colonic Neoplasms Neoplasm Recurrence Local business Colorectal Neoplasms Febrile neutropenia Thymine |
| Zdroj: | Current problems in cancer. 46(2) |
| ISSN: | 1535-6345 |
| Popis: | For patients with refractory metastatic colorectal cancer (mCRC) treatment with Trifluridine/Tipiracil, also known as TAS-102, improves overall survival. This study aims to investigate the efficacy and safety of TAS-102 in a real-world population from Victoria, Australia. A retrospective analysis of prospectively collected data from the Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) registry was undertaken. The characteristics and outcomes of patients receiving TAS-102 were assessed and compared to those enrolled in the registration study (RECOURSE). Across 13 sites, 107 patients were treated with TAS-102. The median age was 60 years (range: 31-83), compared to 63 for RECOURSE. Comparing registry TAS-102-treated and RECOURSE patients, 75% vs 100% were ECOG performance status 0-1, 74% vs 79% had initiated treatment more than 18 months from diagnosis of metastatic disease and 36% vs 49% were RAS wild-type. Median time on treatment was 10.4 weeks (range: 1.7-32). Median progression-free survival (PFS) was 3.3 months compared to 2 months in RECOURSE, while median overall survival was the same at 7.1 months. Two patients (2.3%) had febrile neutropenia and there were no treatment-related deaths, where TAS-102 dose at treatment initiation was at clinician discretion.TRACC registry patients treated with TAS-102 were younger than those from the RECOURSE trial, with similar overall survival observed. Less strict application of RECIST criteria and less frequent imaging may have contributed to an apparently longer PFS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect